Clinical trial
Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload
NCT00379483 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2002
- Completion date
- April 30, 2003
- Enrollment
- 66 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
transfusional iron overload